| abstract |
Antibody prodrugs that can be selectively activated by the protease KLK6 in the central nervous system (CNS) include antibodies for treating a disease or disorder in the CNS, fusion to the N-terminus of the heavy and / or light chains of the antibody. And a blocker fused to the N-terminus of the KLK6 cleavable peptide. The disease or disorder is a cancer, an inflammatory disease, an autoimmune disease, an infectious disease, or a neuronal degenerative disease. |